Business Context and Reporting Period
Company: Hercules Technology Growth Capital, Inc. (HTGC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2011
Business Overview: HTGC is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and a Regulated Investment Company (RIC). It provides debt and equity growth capital to technology-related companies, primarily in life sciences, clean technology, and lower middle market technology sectors.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2011 | Three Months Ended June 30, 2011 |
|---|---|---|
| Total Assets | $691.3 million | $691.3 million |
| Total Investments (at value) | $475.2 million | $475.2 million |
| Cash and Cash Equivalents | $198.2 million | $198.2 million |
| Net Investment Income | $20.2 million | $10.4 million |
| Net Realized Gain on Investments | $5.0 million | $0.7 million |
| Net Unrealized Gain (Loss) | ($2.1 million) | $13.3 million |
| Net Increase in Net Assets from Operations | $23.1 million | $24.3 million |
| Net Asset Value (NAV) per Share | $9.67 | $9.67 |
| Weighted Average Shares Outstanding | 42.8 million | 43.0 million |
| Total Liabilities | $267.4 million | $267.4 million |
| Long-term Debt (SBA Debentures) | $188.8 million | $188.8 million |
| Convertible Senior Notes | $69.8 million (carrying value) | $69.8 million (carrying value) |
Material Changes vs. Prior Period
- Investment Income Growth: Total investment income increased to $40.0 million for the six months ended June 30, 2011, compared to $27.0 million in the same period of 2010. This was driven by a larger average interest-earning portfolio and accelerated fee income from early repayments.
- Operating Expenses: Total operating expenses rose to $19.8 million (six months 2011) from $14.5 million (six months 2010). Increases were attributed to interest expense on new Convertible Senior Notes, higher employee compensation due to headcount growth, and increased general and administrative costs.
- Realized Gains: Net realized gains were $5.0 million for the six months ended June 30, 2011, compared to $3.7 million in the prior year period. This included $10.1 million in gains from the sale of common stock in public portfolio companies, partially offset by $5.1 million in losses from liquidated investments.
- Unrealized Appreciation: The six-month period saw a net unrealized depreciation of $2.1 million, contrasting with a net unrealized depreciation of $15.1 million in the prior year. The three-month period ended June 30, 2011, showed a significant net unrealized appreciation of $13.3 million.
- Debt Issuance: In April 2011, the company issued $75.0 million in 6.00% Convertible Senior Notes due 2016, increasing total debt obligations.
Guidance, Outlook, Risks, and Unusual Items
- Capital Resources: The company reported strong liquidity with $198.2 million in cash and approximately $131.25 million in available borrowing capacity (Wells Facility, Union Bank Facility, and remaining SBA capacity).
- Dividends: The Board declared a quarterly dividend of $0.22 per share for the second quarter, payable September 15, 2011. The company intends to distribute approximately 90-100% of taxable income.
- Internal Control Weakness: Management identified a material weakness in internal control over financial reporting related to manual input errors in valuation calculations. While remediation steps were implemented in Q2 2011, management concluded that controls were not yet effective as of June 30, 2011, due to insufficient evidence of sustained effectiveness.
- Portfolio Concentration: Significant investments (greater than 5% of net assets) include Aveo Pharmaceuticals (7.3%), Women's Marketing Inc. (6.9%), and Pacira Pharmaceuticals (6.1%).
- Market Risk: Approximately 89.2% of portfolio loans are at variable rates. The company does not currently engage in hedging activities.
- Subsequent Events: As of August 4, 2011, the company had closed commitments of $46.0 million and pending commitments of $214.3 million. Horizon Pharma completed its IPO in July 2011.
Investor Verification Checklist
- Internal Control Remediation: Verify the status of remediation efforts regarding the material weakness in valuation calculations and the timeline for declaring controls effective.
- Debt Covenants: Confirm compliance with financial covenants, specifically the minimum tangible net worth requirements under the Wells Facility and Union Bank Facility.
- Portfolio Valuation: Review the fair value methodology for Level 3 assets, given that 68.7% of total assets are valued by the Board of Directors without readily available market quotes.
- Dividend Sustainability: Assess the ratio of net investment income to dividends declared to ensure distributions are covered by earnings and not primarily returns of capital.
- Convertible Notes Impact: Monitor the dilution potential of the $75 million Convertible Senior Notes and the associated interest expense accretion.